XTL Biopharmaceuticals Debt/Equity Ratio 2010-2024 | XTLB

XTL Biopharmaceuticals debt/equity ratio from 2010 to 2024. Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.

XTL Biopharmaceuticals Debt/Equity Ratio 2010-2024 | XTLB

XTL Biopharmaceuticals debt/equity ratio from 2010 to 2024. Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$87.5B
Takeda Pharmaceutical (TAK)$47.5B
Merck (MKGAF)$24.4B
Astellas Pharma (ALPMY)$22B
Sandoz Group AG (SDZNY)$17.6B
Summit Therapeutics (SMMT)$16.8B
United Therapeutics (UTHR)$15.6B
Shionogi (SGIOY)$13.3B
Neurocrine Biosciences (NBIX)$12.2B
Catalent (CTLT)$10.9B
Revolution Medicines (RVMD)$7.7B
Orion OYJ (ORINY)$7.4B
Jazz Pharmaceuticals (JAZZ)$6.9B
Ionis Pharmaceuticals (IONS)$6.2B
Hikma Pharmaceuticals Plc (HKMPF)$5.7B
Madrigal Pharmaceuticals (MDGL)$5.3B
Crinetics Pharmaceuticals (CRNX)$4.3B
Corcept Therapeutics (CORT)$4.3B
Dyne Therapeutics (DYN)$3.7B
PTC Therapeutics (PTCT)$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.7B
Arrowhead Pharmaceuticals (ARWR)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.5B
Soleno Therapeutics (SLNO)$2B
Recursion Pharmaceuticals (RXRX)$2B
Centessa Pharmaceuticals (CNTA)$1.8B
BioCryst Pharmaceuticals (BCRX)$1.7B
Xencor (XNCR)$1.7B
Harrow (HROW)$1.6B
Cassava Sciences (SAVA)$1.5B